Entries by gatekeeper

Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells

15th September 2020 in /by

First detailed, empirical analysis of Class 1 epitopes presented by SARS-Cov-2 infected cells which define the T-Cell repertoire necessary for cytotoxic T-Cell function MHC expression library provides an accurate basis for COVID-19 T-Cell vaccine and related diagnostics development Doylestown PA, USA and Abingdon, Oxon, UK, 15 September 2020– Emergex Vaccines Holding Limited (‘Emergex’), a company […]

Emergex Vaccines forms US subsidiary (Emergex USA) by acquisition of laboratories, technology and assets of US-based T cell specialist biotech ImmProNano

1st September 2020 in /by

Acquisition brings critical technical pre-clinical vaccine development capabilities in-house and establishes US based Emergex subsidiary Emergex uniquely develops novel 100% synthetic ‘set-point’ T cell priming vaccines to address some of the world’s most pathogenic infectious diseases Current COVID-19 pandemic and ongoing threat of pandemic flu demonstrate urgent global need for safe, effective vaccines which can […]

Emergex and Bio-Manguinhos/Fiocruz Elucidate T Cell Epitopes Produced by Commercial Yellow Fever Vaccine

19th August 2020 in /by

First identification of epitopes which shape CD8 T cell response to commercial live attenuated vaccine has implications across RNA virus vaccine development Vaccine primes immune system against T cell epitopes that would be minor or subdominant in a natural infection and are derived from internal proteins Abingdon, UK and Rio de Janeiro, Brazil, 19 August […]

Emergex Signs Agreement with George Mason University for Highly Pathogenic RNA Virus Studies

22nd April 2020 in /by

Emergex Vaccines and George Mason University’s (Mason) National Center for Biodefense and Infectious Diseases (NCBID) enter into an agreement relating to the development of CD8+ priming RNA virus vaccines In particular, NCBID researchers will partner to provide additional expertise, resources, and vital samples to complement Emergex’s existing vaccine programs, including for SARS-CoV-2 Abingdon, UK, 22 […]

Emergex Raises More Than US$11 million in a Series A Round to Progress its Pipeline of Set-point Vaccines for Infectious Diseases

9th January 2020 in /by

Emergex develops set-point vaccines to prevent some of the world’s most immediate and virulent diseases such as Zika, Dengue Fever, Ebola and pandemic Flu Vickers Venture Partners led the fundraising and Dr Finian Tan, Chairman of Vickers Venture Partners joins Emergex’s Board of Directors Capital supports pipeline developments, including progressing its first-in-man Flavivirus (Dengue) vaccine […]

Emergex Signs an R&D Agreement with IMCB to Develop a Vaccine for the Emerging Threat of Hand, Foot & Mouth Disease

27th June 2019 in /by

Emergex today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD). Emergex and IMCB will collaborate closely to develop the new vaccine, combining their personnel, specialist knowledge and expertise.